BACKGROUND Severe acute respiratory syndrome coronavirus 2,or coronavirus disease-2019(COVID-19),has infected millions worldwide since its discovery in Wuhan,China in December 2019,but little is still known about the ...BACKGROUND Severe acute respiratory syndrome coronavirus 2,or coronavirus disease-2019(COVID-19),has infected millions worldwide since its discovery in Wuhan,China in December 2019,but little is still known about the disease process.Preliminary research in China notes liver function tests(LFTs)abnormalities are common in COVID-19 patients,suggesting decreased hepatic function,and that abnormalities in LFTs are related to complicated disease course and negative outcomes.However,there has been limited large-scale data assessing COVID-19’s association with liver dysfunction and negative outcomes.AIM To investigate how COVID-19 affects the liver function and disease course in patients infected with the virus treated at Henry Ford Hospital from March to September 2020.METHODS A total of 8028 patients infected with COVID-19 were identified and included in the study at a single academic center.Data from medical charts on laboratory testing including aspartate aminotransferase(AST),alanine aminotransferase(ALT),alkaline phosphatase(AP),and bilirubin levels,past history of liver disease,and disease course indicators including hospital admission,intensive care unit(ICU)admission,intubation,and death were recorded and analyzed.Elevated liver enzymes were defined as ALT/AST greater than 60,AP greater than 150,or bilirubin greater than 1.5,super-elevated liver enzymes were defined as ALT/AST greater than 120,AP greater than 300,or bilirubin greater than 3.0.RESULTS A total of 8028 COVID-19 patients were identified and included in the study.Data from medical charts on LFTs(namely,AST,ALT,AP,and bilirubin levels),past history of liver disease,and disease course indicators(hospital/ICU admission,intubation,death)were recorded and analyzed.LFTs from 3937 patients were available for interpretation.45% were found to have elevated or super-elevated LFT.When compared to COVID-19 patients without elevated LFTs,this cohort was found to have significantly higher odds of hospital admittance,ICU admission,intubation,and death(all P<0.001).248(3.1%)had a history of liver disease.Those with elevated and super elevated LFTS had significantly higher odds of having a past history of liver disease(P<0.001).CONCLUSION The findings from this study suggest that in patients who have tested positive for COVID-19,those with elevated and super elevated liver enzyme levels have significantly higher odds of hospital admittance,ICU admittance,intubation and death in comparison to those COVID-19 patients without elevated liver enzyme levels.展开更多
Objective To investigate the effects of different doses of atorvastatin on plasma endothelin and platelet function in acute ST-segment elevation myocardial infarction(STEMI)patients after emergency percutaneous corona...Objective To investigate the effects of different doses of atorvastatin on plasma endothelin and platelet function in acute ST-segment elevation myocardial infarction(STEMI)patients after emergency percutaneous coronary intervention(PCI).Methods A total of 120 patients with acute STEMI treated with emergency PCI were enrolled and randomly divided into 20 mg of atorvastatin treatment group(standard group,n=60),and 40 mg of atorvastatin treatment group(intensive group,n=60).展开更多
文摘BACKGROUND Severe acute respiratory syndrome coronavirus 2,or coronavirus disease-2019(COVID-19),has infected millions worldwide since its discovery in Wuhan,China in December 2019,but little is still known about the disease process.Preliminary research in China notes liver function tests(LFTs)abnormalities are common in COVID-19 patients,suggesting decreased hepatic function,and that abnormalities in LFTs are related to complicated disease course and negative outcomes.However,there has been limited large-scale data assessing COVID-19’s association with liver dysfunction and negative outcomes.AIM To investigate how COVID-19 affects the liver function and disease course in patients infected with the virus treated at Henry Ford Hospital from March to September 2020.METHODS A total of 8028 patients infected with COVID-19 were identified and included in the study at a single academic center.Data from medical charts on laboratory testing including aspartate aminotransferase(AST),alanine aminotransferase(ALT),alkaline phosphatase(AP),and bilirubin levels,past history of liver disease,and disease course indicators including hospital admission,intensive care unit(ICU)admission,intubation,and death were recorded and analyzed.Elevated liver enzymes were defined as ALT/AST greater than 60,AP greater than 150,or bilirubin greater than 1.5,super-elevated liver enzymes were defined as ALT/AST greater than 120,AP greater than 300,or bilirubin greater than 3.0.RESULTS A total of 8028 COVID-19 patients were identified and included in the study.Data from medical charts on LFTs(namely,AST,ALT,AP,and bilirubin levels),past history of liver disease,and disease course indicators(hospital/ICU admission,intubation,death)were recorded and analyzed.LFTs from 3937 patients were available for interpretation.45% were found to have elevated or super-elevated LFT.When compared to COVID-19 patients without elevated LFTs,this cohort was found to have significantly higher odds of hospital admittance,ICU admission,intubation,and death(all P<0.001).248(3.1%)had a history of liver disease.Those with elevated and super elevated LFTS had significantly higher odds of having a past history of liver disease(P<0.001).CONCLUSION The findings from this study suggest that in patients who have tested positive for COVID-19,those with elevated and super elevated liver enzyme levels have significantly higher odds of hospital admittance,ICU admittance,intubation and death in comparison to those COVID-19 patients without elevated liver enzyme levels.
文摘Objective To investigate the effects of different doses of atorvastatin on plasma endothelin and platelet function in acute ST-segment elevation myocardial infarction(STEMI)patients after emergency percutaneous coronary intervention(PCI).Methods A total of 120 patients with acute STEMI treated with emergency PCI were enrolled and randomly divided into 20 mg of atorvastatin treatment group(standard group,n=60),and 40 mg of atorvastatin treatment group(intensive group,n=60).
